View ValuationLiaoning OxiranchemInc 将来の成長Future 基準チェック /06現在、 Liaoning OxiranchemIncの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長28.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 30Liaoning Oxiranchem,Inc. to Report First Half, 2026 Results on Aug 25, 2026Liaoning Oxiranchem,Inc. announced that they will report first half, 2026 results on Aug 25, 2026お知らせ • Apr 28Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026, at 15:30 China Standard Time. Location: The Company's Meeting Room, Shanghai Chinaお知らせ • Mar 31Liaoning Oxiranchem,Inc. to Report Q1, 2026 Results on Apr 28, 2026Liaoning Oxiranchem,Inc. announced that they will report Q1, 2026 results on Apr 28, 2026お知らせ • Dec 31Liaoning Oxiranchem,Inc. to Report Fiscal Year 2025 Results on Apr 28, 2026Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2025 results on Apr 28, 2026お知らせ • Sep 30Liaoning Oxiranchem,Inc. to Report Q3, 2025 Results on Oct 27, 2025Liaoning Oxiranchem,Inc. announced that they will report Q3, 2025 results on Oct 27, 2025お知らせ • Sep 12Liaoning Oxiranchem,Inc. Approves Board AppointmentsLiaoning Oxiranchem,Inc. at its EGM held on September 10, 2025, approved the appointment of Ren Jiangang and Liu Guocheng as independent directors.お知らせ • Jul 02Liaoning Oxiranchem,Inc. to Report First Half, 2025 Results on Aug 26, 2025Liaoning Oxiranchem,Inc. announced that they will report first half, 2025 results on Aug 26, 2025お知らせ • Apr 22Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2025Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: No. 38, Wanhe 7th Road, Hongwei District, Liaoyang, Liaoning Chinaお知らせ • Mar 31Liaoning Oxiranchem,Inc. to Report Q1, 2025 Results on Apr 22, 2025Liaoning Oxiranchem,Inc. announced that they will report Q1, 2025 results on Apr 22, 2025お知らせ • Dec 31Liaoning Oxiranchem,Inc. to Report Fiscal Year 2024 Results on Apr 22, 2025Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2024 results on Apr 22, 2025Reported Earnings • Oct 28Third quarter 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.061 loss in 3Q 2023)Third quarter 2024 results: CN¥0.05 loss per share (improved from CN¥0.061 loss in 3Q 2023). Revenue: CN¥1.17b (up 24% from 3Q 2023). Net loss: CN¥32.7m (loss narrowed 25% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.お知らせ • Sep 30Liaoning Oxiranchem,Inc. to Report Q3, 2024 Results on Oct 28, 2024Liaoning Oxiranchem,Inc. announced that they will report Q3, 2024 results on Oct 28, 2024New Risk • Sep 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).Reported Earnings • Aug 06Second quarter 2024 earnings released: CN¥0.032 loss per share (vs CN¥0.13 loss in 2Q 2023)Second quarter 2024 results: CN¥0.032 loss per share (improved from CN¥0.13 loss in 2Q 2023). Revenue: CN¥1.08b (down 2.1% from 2Q 2023). Net loss: CN¥22.4m (loss narrowed 75% from 2Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.お知らせ • Jun 29Liaoning Oxiranchem,Inc. to Report First Half, 2024 Results on Aug 06, 2024Liaoning Oxiranchem,Inc. announced that they will report first half, 2024 results on Aug 06, 2024Reported Earnings • Apr 24First quarter 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.09 loss in 1Q 2023)First quarter 2024 results: CN¥0.12 loss per share (further deteriorated from CN¥0.09 loss in 1Q 2023). Revenue: CN¥757.1m (down 19% from 1Q 2023). Net loss: CN¥78.4m (loss widened 30% from 1Q 2023).お知らせ • Apr 23Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2024Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: No. 38, Wanhe 7th Road, Hongwei District, Liaoyang, Liaoning ChinaNew Risk • Apr 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).お知らせ • Mar 30Liaoning Oxiranchem,Inc. to Report Q1, 2024 Results on Apr 23, 2024Liaoning Oxiranchem,Inc. announced that they will report Q1, 2024 results on Apr 23, 2024New Risk • Mar 21New major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.お知らせ • Dec 30Liaoning Oxiranchem,Inc. to Report Fiscal Year 2023 Results on Apr 23, 2024Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2023 results on Apr 23, 2024Reported Earnings • Oct 26Third quarter 2023 earnings released: CN¥0.061 loss per share (vs CN¥0.067 loss in 3Q 2022)Third quarter 2023 results: CN¥0.061 loss per share. Revenue: CN¥949.3m (down 35% from 3Q 2022). Net loss: CN¥43.6m (loss widened 12% from 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China.Reported Earnings • Aug 29Second quarter 2023 earnings released: CN¥0.13 loss per share (vs CN¥0.074 loss in 2Q 2022)Second quarter 2023 results: CN¥0.13 loss per share (further deteriorated from CN¥0.074 loss in 2Q 2022). Revenue: CN¥1.10b (down 30% from 2Q 2022). Net loss: CN¥89.8m (loss widened 73% from 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.Reported Earnings • Apr 19Full year 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.52 in FY 2021)Full year 2022 results: EPS: CN¥0.01 (down from CN¥0.52 in FY 2021). Revenue: CN¥5.64b (down 16% from FY 2021). Net income: CN¥5.60m (down 98% from FY 2021). Profit margin: 0.1% (down from 5.2% in FY 2021).Valuation Update With 7 Day Price Move • Mar 31Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥10.05, the stock trades at a trailing P/E ratio of 40.8x. Average trailing P/E is 28x in the Chemicals industry in China. Total loss to shareholders of 6.5% over the past year.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 29Third quarter 2022 earnings released: CN¥0.031 loss per share (vs CN¥0.16 profit in 3Q 2021)Third quarter 2022 results: CN¥0.031 loss per share (down from CN¥0.16 profit in 3Q 2021). Revenue: CN¥1.46b (down 22% from 3Q 2021). Net loss: CN¥39.0m (down 136% from profit in 3Q 2021). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.Board Change • Oct 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 20% share price gain to CN¥11.15, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 17x in the Chemicals industry in China.Reported Earnings • Aug 24Second quarter 2022 earnings released: CN¥0.074 loss per share (vs CN¥0.043 profit in 2Q 2021)Second quarter 2022 results: CN¥0.074 loss per share (down from CN¥0.043 profit in 2Q 2021). Revenue: CN¥1.58b (down 9.0% from 2Q 2021). Net loss: CN¥52.0m (down 261% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 22%, compared to a 42% growth forecast for the Chemicals industry in China.Reported Earnings • Apr 30First quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.08 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.08 in 1Q 2021). Revenue: CN¥1.34b (down 3.1% from 1Q 2021). Net income: CN¥99.7m (up 95% from 1Q 2021). Profit margin: 7.4% (up from 3.7% in 1Q 2021). The increase in margin was driven by lower expenses.Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Enjun Song was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 18Full year 2021 earnings released: EPS: CN¥0.53 (vs CN¥0.59 in FY 2020)Full year 2021 results: EPS: CN¥0.53 (down from CN¥0.59 in FY 2020). Revenue: CN¥6.72b (up 18% from FY 2020). Net income: CN¥357.2m (down 11% from FY 2020). Profit margin: 5.3% (down from 7.1% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 26%, compared to a 48% growth forecast for the industry in China.Board Change • Dec 10High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Enjun Song was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Liaoning OxiranchemInc は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測XSEC:300082 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20264,35412-118-100N/A12/31/20254,2257-487-466N/A9/30/20254,435-32-214N/A6/30/20254,493-57-158-131N/A3/31/20254,473-84-373-345N/A12/31/20244,287-159-68-40N/A9/30/20243,833-249-549-524N/A6/30/20243,609-260-394-363N/A3/31/20243,632-327-191-154N/A12/31/20233,813-3091787N/A9/30/20234,254-19722217N/A6/30/20234,760-19295305N/A3/31/20235,237-154184400N/A1/1/20235,639648306N/A9/30/20226,103168236495N/A6/30/20226,52031796357N/A3/31/20226,675401331568N/A1/1/20226,71735210497N/A9/30/20216,785291-278270N/A6/30/20216,470345-174497N/A3/31/20216,336440-152535N/A12/31/20205,708403257623N/A9/30/20205,719415446696N/A6/30/20205,758361732844N/A3/31/20205,697308695805N/A12/31/20196,389352N/A1,285N/A9/30/20196,410316N/A1,595N/A6/30/20197,098333N/A1,236N/A3/31/20197,667353N/A1,326N/A12/31/20187,449326N/A720N/A9/30/20187,421304N/A83N/A6/30/20186,655254N/A320N/A3/31/20185,895214N/A49N/A12/31/20175,699209N/A139N/A9/30/20175,254140N/A338N/A6/30/20174,945125N/A240N/A3/31/20174,596115N/A54N/A12/31/20164,34776N/A216N/A9/30/20163,831-22N/A-148N/A6/30/20163,415-188N/A-167N/A3/31/20163,157-226N/A11N/A12/31/20152,965-210N/A1N/A9/30/20152,804-94N/A-61N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 300082の予測収益成長が 貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 300082の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 300082の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 300082の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 300082の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 300082の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 03:43終値2026/07/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Liaoning Oxiranchem,Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Di WuChina International Capital Corporation LimitedNai Di ZhaoEverbright Securities Co. Ltd.Fangbiao ZhengIndustrial Securities Co. Ltd.
お知らせ • Jun 30Liaoning Oxiranchem,Inc. to Report First Half, 2026 Results on Aug 25, 2026Liaoning Oxiranchem,Inc. announced that they will report first half, 2026 results on Aug 25, 2026
お知らせ • Apr 28Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2026, at 15:30 China Standard Time. Location: The Company's Meeting Room, Shanghai China
お知らせ • Mar 31Liaoning Oxiranchem,Inc. to Report Q1, 2026 Results on Apr 28, 2026Liaoning Oxiranchem,Inc. announced that they will report Q1, 2026 results on Apr 28, 2026
お知らせ • Dec 31Liaoning Oxiranchem,Inc. to Report Fiscal Year 2025 Results on Apr 28, 2026Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2025 results on Apr 28, 2026
お知らせ • Sep 30Liaoning Oxiranchem,Inc. to Report Q3, 2025 Results on Oct 27, 2025Liaoning Oxiranchem,Inc. announced that they will report Q3, 2025 results on Oct 27, 2025
お知らせ • Sep 12Liaoning Oxiranchem,Inc. Approves Board AppointmentsLiaoning Oxiranchem,Inc. at its EGM held on September 10, 2025, approved the appointment of Ren Jiangang and Liu Guocheng as independent directors.
お知らせ • Jul 02Liaoning Oxiranchem,Inc. to Report First Half, 2025 Results on Aug 26, 2025Liaoning Oxiranchem,Inc. announced that they will report first half, 2025 results on Aug 26, 2025
お知らせ • Apr 22Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2025Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: No. 38, Wanhe 7th Road, Hongwei District, Liaoyang, Liaoning China
お知らせ • Mar 31Liaoning Oxiranchem,Inc. to Report Q1, 2025 Results on Apr 22, 2025Liaoning Oxiranchem,Inc. announced that they will report Q1, 2025 results on Apr 22, 2025
お知らせ • Dec 31Liaoning Oxiranchem,Inc. to Report Fiscal Year 2024 Results on Apr 22, 2025Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2024 results on Apr 22, 2025
Reported Earnings • Oct 28Third quarter 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.061 loss in 3Q 2023)Third quarter 2024 results: CN¥0.05 loss per share (improved from CN¥0.061 loss in 3Q 2023). Revenue: CN¥1.17b (up 24% from 3Q 2023). Net loss: CN¥32.7m (loss narrowed 25% from 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
お知らせ • Sep 30Liaoning Oxiranchem,Inc. to Report Q3, 2024 Results on Oct 28, 2024Liaoning Oxiranchem,Inc. announced that they will report Q3, 2024 results on Oct 28, 2024
New Risk • Sep 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).
Reported Earnings • Aug 06Second quarter 2024 earnings released: CN¥0.032 loss per share (vs CN¥0.13 loss in 2Q 2023)Second quarter 2024 results: CN¥0.032 loss per share (improved from CN¥0.13 loss in 2Q 2023). Revenue: CN¥1.08b (down 2.1% from 2Q 2023). Net loss: CN¥22.4m (loss narrowed 75% from 2Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
お知らせ • Jun 29Liaoning Oxiranchem,Inc. to Report First Half, 2024 Results on Aug 06, 2024Liaoning Oxiranchem,Inc. announced that they will report first half, 2024 results on Aug 06, 2024
Reported Earnings • Apr 24First quarter 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.09 loss in 1Q 2023)First quarter 2024 results: CN¥0.12 loss per share (further deteriorated from CN¥0.09 loss in 1Q 2023). Revenue: CN¥757.1m (down 19% from 1Q 2023). Net loss: CN¥78.4m (loss widened 30% from 1Q 2023).
お知らせ • Apr 23Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2024Liaoning Oxiranchem,Inc., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: No. 38, Wanhe 7th Road, Hongwei District, Liaoyang, Liaoning China
New Risk • Apr 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
お知らせ • Mar 30Liaoning Oxiranchem,Inc. to Report Q1, 2024 Results on Apr 23, 2024Liaoning Oxiranchem,Inc. announced that they will report Q1, 2024 results on Apr 23, 2024
New Risk • Mar 21New major risk - Revenue and earnings growthEarnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
お知らせ • Dec 30Liaoning Oxiranchem,Inc. to Report Fiscal Year 2023 Results on Apr 23, 2024Liaoning Oxiranchem,Inc. announced that they will report fiscal year 2023 results on Apr 23, 2024
Reported Earnings • Oct 26Third quarter 2023 earnings released: CN¥0.061 loss per share (vs CN¥0.067 loss in 3Q 2022)Third quarter 2023 results: CN¥0.061 loss per share. Revenue: CN¥949.3m (down 35% from 3Q 2022). Net loss: CN¥43.6m (loss widened 12% from 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China.
Reported Earnings • Aug 29Second quarter 2023 earnings released: CN¥0.13 loss per share (vs CN¥0.074 loss in 2Q 2022)Second quarter 2023 results: CN¥0.13 loss per share (further deteriorated from CN¥0.074 loss in 2Q 2022). Revenue: CN¥1.10b (down 30% from 2Q 2022). Net loss: CN¥89.8m (loss widened 73% from 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
Reported Earnings • Apr 19Full year 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.52 in FY 2021)Full year 2022 results: EPS: CN¥0.01 (down from CN¥0.52 in FY 2021). Revenue: CN¥5.64b (down 16% from FY 2021). Net income: CN¥5.60m (down 98% from FY 2021). Profit margin: 0.1% (down from 5.2% in FY 2021).
Valuation Update With 7 Day Price Move • Mar 31Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥10.05, the stock trades at a trailing P/E ratio of 40.8x. Average trailing P/E is 28x in the Chemicals industry in China. Total loss to shareholders of 6.5% over the past year.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 29Third quarter 2022 earnings released: CN¥0.031 loss per share (vs CN¥0.16 profit in 3Q 2021)Third quarter 2022 results: CN¥0.031 loss per share (down from CN¥0.16 profit in 3Q 2021). Revenue: CN¥1.46b (down 22% from 3Q 2021). Net loss: CN¥39.0m (down 136% from profit in 3Q 2021). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.
Board Change • Oct 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. 3 highly experienced directors. Independent Director Xinping Bu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Sep 07Investor sentiment improved over the past weekAfter last week's 20% share price gain to CN¥11.15, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 17x in the Chemicals industry in China.
Reported Earnings • Aug 24Second quarter 2022 earnings released: CN¥0.074 loss per share (vs CN¥0.043 profit in 2Q 2021)Second quarter 2022 results: CN¥0.074 loss per share (down from CN¥0.043 profit in 2Q 2021). Revenue: CN¥1.58b (down 9.0% from 2Q 2021). Net loss: CN¥52.0m (down 261% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 22%, compared to a 42% growth forecast for the Chemicals industry in China.
Reported Earnings • Apr 30First quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.08 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.15 (up from CN¥0.08 in 1Q 2021). Revenue: CN¥1.34b (down 3.1% from 1Q 2021). Net income: CN¥99.7m (up 95% from 1Q 2021). Profit margin: 7.4% (up from 3.7% in 1Q 2021). The increase in margin was driven by lower expenses.
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Enjun Song was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 18Full year 2021 earnings released: EPS: CN¥0.53 (vs CN¥0.59 in FY 2020)Full year 2021 results: EPS: CN¥0.53 (down from CN¥0.59 in FY 2020). Revenue: CN¥6.72b (up 18% from FY 2020). Net income: CN¥357.2m (down 11% from FY 2020). Profit margin: 5.3% (down from 7.1% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 26%, compared to a 48% growth forecast for the industry in China.
Board Change • Dec 10High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Independent Director Enjun Song was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.